Hence, in fibrotic CKD, the optimal therapeutic window for NRF2 modulators would likely be in early fibrosis, prior to extensive inflammation and the accumulation of uremic toxins that may irreversibly impair the NRF2 response. This evidence concerns the gene NFE2L2 and chronic kidney disease.